SIZE
96 wells/kit
INTENDED USE
The ImmunoDiagnostics SARS-CoV2 S1RBD-ACE2 Binding Assay is designed to measure the interaction between the receptor binding domain of the viral spike glycoprotein (S1RBD) with the cell surface receptor ACE2. The assay can detect the presence of neutralizing antibodies in human plasma or serum after infection or vaccination.
This product is intended for research use only.
BACKGROUND
The ongoing global pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is an enveloped virus with a positive-sense RNA genome and a nucleocapsid of helical symmetry. The SARS-CoV-2 entry into host cells is mediated by the transmembrane spike (S) glycoprotein, which contains a receptor binding domain (RBD). S1RBD is responsible for binding with angiotensin converting enzyme-2 (ACE2), leading to endocytosis into the host cells and viral replication. S1RBD is the main target of neutralizing antibodies upon infection and the focus of the therapeutic drug and vaccine design. Molecules that inhibit formation of the S1RBD-ACE2 complex in vitro could be potential treatment for COVID-19 infection.
SIZE
96 wells/kit
INTENDED USE
The ImmunoDiagnostics SARS-CoV2 S1RBD-ACE2 Binding Assay is designed to measure the interaction between the receptor binding domain of the viral spike glycoprotein (S1RBD) with the cell surface receptor ACE2. The assay can detect the presence of neutralizing antibodies in human plasma or serum after infection or vaccination.
This product is intended for research use only.
BACKGROUND
The ongoing global pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is an enveloped virus with a positive-sense RNA genome and a nucleocapsid of helical symmetry. The SARS-CoV-2 entry into host cells is mediated by the transmembrane spike (S) glycoprotein, which contains a receptor binding domain (RBD). S1RBD is responsible for binding with angiotensin converting enzyme-2 (ACE2), leading to endocytosis into the host cells and viral replication. S1RBD is the main target of neutralizing antibodies upon infection and the focus of the therapeutic drug and vaccine design. Molecules that inhibit formation of the S1RBD-ACE2 complex in vitro could be potential treatment for COVID-19 infection.
